BBNX (Beta Bionics) Net Profit

Corporate emblem and logo of betabionics.com (BBNX)

The price trajectory of Beta Bionics Inc (BBNX) reflects the dynamics of a company creating a bionic pancreas in a rapid growth phase through partnerships with endocrinologists. The indicator stands at -0.08. The business relies on the production of insulin pumps while facing market inertia and a dependence on insurance coverage. Critical threats remain potential certification delays for systems and software technical errors amid pressure from tech giants.

BBNX: Beta Bionics Inc Net Profit 01/31/2025 - 10/31/2026

Financial and market metric breakdowns for Beta Bionics (BBNX)

- current quotes and average value forecast:
Market Chart iLet Bionic Pancreas|BBNX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization iLet Bionic Pancreas|BBNX - Total Company Value
- book capitalization data:
Net Assets per Single Share Beta Bionics|BBNX - Book Capitalization|Market Capitalization to Book Value betabionics.com|BBNX - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity Beta Bionics Inc|BBNX - Long-Term Debt to Capital|Current Liabilities to Capital Beta Bionics, Inc.|BBNX - Company Aggregate Debts|Debt to Book Value Ratio iLet Bionic Pancreas|BBNX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Beta Bionics|Quick Liquidity Indicator betabionics.com
- earnings and valuation multiples information:
BBNX - Net Profit
Fundamental valuation:iLet Bionic Pancreas
Product sample of Beta Bionics Inc

This indicator serves as a key filter for assessing the investment reliability of the issuer. The metric measures the real-time market consensus on yield, eliminating the time lag of traditional reporting through an analysis of daily profit fluctuations. By studying the company's profit history, an investor determines the stage between market euphoria and capital capitulation. For Beta Bionics Inc (BBNX), the trend of this indicator reflects the actual efficiency of the commercial implementation of medtech. This allows for an objective assessment of the advance confidence placed in the young management team.

Key competitors

BSX - Net Financial Result|EW (Edwards Lifesciences) - Net Profit|Net Profit resmed.com|Company Net Income Insulet (PODD)|Company Net Income ZBH (Zimmer Biomet Holdings)|Net Profit COO (CooperVision)|Net Financial Result Align Corp (ALGN)|GMED: Net Income|Profit After Tax TMDX|ATEC: Net Profit|Company Net Income CryoLife (AORT)|ENOV (DJO Global) - Net Profit|Company Profit IART (Integra LifeSciences Inc.)|Net Income ESTA (Establishment Labs)|IRMD (iradimed.com) - Final Profit|Company Net Income Embecta EMBC|TNDM - Net Income|Axogen Corp - Net Profit|Company Net Income SI-BONE Medical|OFIX: Net Profit|Company Profit BVS|KIDS (OrthoPediatrics Corp) - Net Profit|Treace Medical Concepts Inc (TMCI) - Net Financial Result|Net Profit SRTA|Net Income Carlsmed Medical CARL|Net Profit RXST (RxSight, Inc.)|Net Profit ClearPoint Neuro Inc. CLPT|STXS - Company Net Income|STIM: Company Net Income|SGHT (Sight Sciences, Inc) - Net Income|Orchestra BioMed Inc. - Final Profit|ANIK (Anika Therapeutics Inc.) - Net Profit|Company Net Income inspiremd.com NSPR|Company Net Income Jin Medical International (ZJYL)|vivani.com (VANI) - Annual Net Income|Xtant Medical - Net Income|Net Profit NeuroOne Medical Technologies Corp. NMTC|Modular Med - Net Profit|Net Financial Result myomo.com MYO|Envoy Medical (COCH) - Company Net Income|Profit After Tax VVOS (Vivos Therapeutics Inc.)|Company Net Income enVVeno|Net Income SINTX Technologies (SINT)|Net Profit TNON|LFWD - Company Net Income|Company Net Income Autonomix Medical AMIX|IVF: Company Profit|BBLG: Net Income|Axonics, Inc - Profit After Payment of Taxes|BIOL: Net Profit|DYNT (Dynatronics) - Company Net Income|FNA (Paragon 28 Inc.) - Net Profit|Company Net Income INVO Bio INVO